COUR Pharmaceuticals
PrivateLast Round
Series B
Jun 18, 2026
Total Funding Raised
$155M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
COUR Pharmaceuticals operates in Healthcare & Life Sciences and is based in Skokie, Illinois. Its latest recorded funding round was a Series B round in June 2026.
COUR Pharmaceuticals is a clinical-stage biotechnology company that develops antigen-specific immune tolerance therapies to treat autoimmune and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
COUR Pharmaceuticals Comparables
Compare COUR Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Imcyse | 86% | |
| Anokion | 85% | |
| Topas Therapeutics | 84% |
For institutional investors. Book with your work email.
COUR Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 18, 2026 | ||||
| Series A | Jan 30, 2024 | ||||
| VC Round | Sep 7, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
COUR Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Roche Venture Fund | Series A, Series B |
| Roche Venture Fund | Series A |
| Angelini Ventures | Series B, Series A |
| JDRF | Series A, Series B |
| Lumira Ventures | Series A, Series B |
| Pfizer | Series A |
| Chimera Capital Management | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 55% MoM.
- Jun 18, 2026
$50M round led by Lumira Ventures and Roche Venture Fund.
For institutional investors. Book with your work email.
COUR Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about COUR Pharmaceuticals's valuation, stock price, and market status.
Is COUR Pharmaceuticals a public or private company?
COUR Pharmaceuticals is a private company.
What is the current stock price of COUR Pharmaceuticals?
COUR Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks COUR Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is COUR Pharmaceuticals worth (valuation)?
Valuation information for COUR Pharmaceuticals is not publicly available.
Can I buy COUR Pharmaceuticals stock?
COUR Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was COUR Pharmaceuticals's last funding round?
COUR Pharmaceuticals's most recent funding round was Series B on June 18, 2026.
Who are the main investors in COUR Pharmaceuticals?
Key investors in COUR Pharmaceuticals include Roche Venture Fund, Angelini Ventures, Lumira Ventures, Alpha Wave Global.
Will COUR Pharmaceuticals IPO soon?
No public IPO plans have been announced for COUR Pharmaceuticals.
How can I track COUR Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in COUR Pharmaceuticals's shares on secondary markets.